[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:somatic-pathogenic-variant":3},{"name":4,"total":5,"recruiting":5,"trials":6},"Somatic pathogenic variant",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04239157","A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS\u002FIPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia",[11],"Phase 2","RECRUITING","2026-08-26T02:16:46.147215Z","2026-05-05T02:43:28.559765Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT04102423","CHIP\u002FCCUS Natural History Protocol",[],"2026-08-26T02:19:19.975067Z","2026-05-13T02:55:06.242219Z"]